KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Long-Term Investments: 2020-2021

Historic Long-Term Investments for Neogenomics (NEO) over the last 1 years, with Mar 2021 value amounting to $29.6 million.

  • Neogenomics' Long-Term Investments was N/A to $29.6 million in Q1 2021 from the same period last year, while for Mar 2021 it was $29.6 million, marking a year-over-year change of. This contributed to the annual value of $29.6 million for FY2020, which is N/A change from last year.
  • As of Q1 2021, Neogenomics' Long-Term Investments stood at $29.6 million, which was down 0.00% from $29.6 million recorded in Q4 2020.
  • Neogenomics' Long-Term Investments' 5-year high stood at $29.6 million during Q4 2020, with a 5-year trough of $13.1 million in Q2 2020.
  • Its 2-year average for Long-Term Investments is $24.5 million, with a median of $27.6 million in 2020.